Kaleido Biosciences to collaborate with BIOASTER and MetaGenoPolis to investigate the health potential of a novel class of therapies targeting the microbiome.

Kaleido Biosciences, a U.S.-based clinical-stage healthcare company, and BIOASTER, the French Technology Research Institute in applied microbiology, announced today the initiation of a collaborative project aiming to evaluate the immunomodulatory and homeostatic potential of the Microbiome Metabolic Therapies (MMT™) - de novo synthetized proprietary glycans developed by Kaleido to improve human health via the gut microbiome. MMTs are designed to modulate the composition and metabolic output of the microbiome by driving the function and distribution of the organ’s existing microbes. The MMT candidates are orally administered, have limited systemic exposure, and are selectively metabolized by enzymes in the microbiome. The current project will leverage the scientific and technical expertise of BIOASTER in the field of the microbiome – host research, including immunomonitoring and transcriptomic analysis capabilities. BIOASTER will team-up with MetaGenoPolis to perform a high throughput screening and select MMTs on specific properties.

"Using our proprietary product platform, we have created a library of more than 1,500 MMT candidates. With their scientific and technical expertise in translational microbiology, BIOASTER with the support of MetaGenoPolis, is the ideal collaborator to help our team advance the development of our MMTs as we work to translate the promise of the microbiome into solutions for patients," said Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer of Kaleido.

"This collaborative program strengthens BIOASTER’s expertise and technology approaches in exploring host-microbiota interactions", said Nathalie Garçon, CEO &CSO of BIOASTER. "We are thrilled to work with Kaleido and MetaGenoPolis teams on this exciting project that should provide new insights into Kaleido’s chemistry-driven approach to leveraging the potential of the microbiome."

"MetaGenoPolis is very enthusiastic to be involved in this collaborative project with BIOASTER and Kaleido, which reinforces our recognition in this field of research," said Hervé Blottière, Ph.D., Scientific director of the MetaFun plateform at MetaGenoPolis.
About BIOASTER:
BIOASTER - created in 2012 - is an IRT, Institute of Technological Research, specialized in microbiology and infectiology.
BIOASTER designs, develops and uses transformative technological innovations to meet the needs of industries. Through collaborative public / private projects, it helps to accelerate the development of medical and nutritional solutions with high added value for the benefit of human and animal health.

BIOASTER is involved in four areas of application:
• Antimicrobials: combating antimicrobial resistance
• Vaccines: improving the safety and efficacy of vaccines
• Microbiota: take full advantage of the human and animal microbiota
• Diagnosis: quickly diagnose infections at the bedside

KEY FIGURES:
• 2450m² of laboratories BSL 2 & 3 (LYON & PARIS)
• 100+ collaborators, 80% of whom are scientific experts, 17 different citizenships
• 66 projects including 27 with private partners, 29 with public partners and 10 international and European projects.

Press contact: olivier.charzat@bioaster.org
www.bioaster.org